Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 2.9%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price dropped 2.9% during trading on Monday . The stock traded as low as $8.03 and last traded at $8.11. Approximately 1,120,668 shares were traded during trading, a decline of 81% from the average daily volume of 6,053,652 shares. The stock had previously closed at $8.35.

Analyst Upgrades and Downgrades

RXRX has been the subject of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $17.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, June 25th. KeyCorp lowered their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th.

Recursion Pharmaceuticals Stock Down 4.1 %

The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -5.07 and a beta of 0.83. The business has a 50 day moving average price of $8.50 and a 200-day moving average price of $9.56.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.04. The firm had revenue of $13.80 million during the quarter, compared to the consensus estimate of $11.10 million. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. Recursion Pharmaceuticals’s revenue for the quarter was up 14.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.34) earnings per share. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $7.95, for a total value of $91,003.65. Following the completion of the transaction, the director now owns 7,218,414 shares of the company’s stock, valued at $57,386,391.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $7.95, for a total value of $91,003.65. Following the completion of the transaction, the director now owns 7,218,414 shares of the company’s stock, valued at $57,386,391.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Secora sold 15,000 shares of the stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $9.32, for a total value of $139,800.00. Following the completion of the transaction, the chief financial officer now directly owns 1,243,468 shares of the company’s stock, valued at approximately $11,589,121.76. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 257,682 shares of company stock valued at $2,083,123. Insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Benjamin F. Edwards & Company Inc. bought a new position in Recursion Pharmaceuticals during the 1st quarter worth approximately $26,000. National Bank of Canada FI lifted its holdings in Recursion Pharmaceuticals by 90.9% during the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after buying an additional 1,500 shares during the last quarter. First Horizon Advisors Inc. bought a new position in Recursion Pharmaceuticals during the 4th quarter worth approximately $47,000. GAMMA Investing LLC lifted its holdings in Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after buying an additional 6,036 shares during the last quarter. Finally, Midwest Financial Group LLC bought a new position in Recursion Pharmaceuticals during the 2nd quarter worth approximately $90,000. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.